Navigation Links
Conformetrix Appoints Dr Sam Williams as Chief Executive Officer
Date:3/7/2012

MANCHESTER, England, March 7, 2012 /PRNewswire/ --

The Board of Conformetrix Ltd, a leader in optimising drug discovery and design, has appointed Dr Sam Williams as Chief Executive Officer, it is announced today. Dr Williams, who has extensive transactional and business development expertise, was previously a Non-Executive Director of the company. He takes over from one of Conformetrix's founder scientists, Dr Andrew Almond, who becomes Chief Technology Officer.

Conformetrix uses its NMR-based technology to determine the accurate bioactive structures of molecules, an approach which has significant potential in the optimisation of drug discovery and design, as well as the generation of novel drugs. By solving dynamic 3D structures independently of techniques such as X-ray crystallography, the Conformetrix approach derives valuable data more quickly and cheaply than standard approaches. It has been validated by studies both in-house and with partners, and further data and partnering deals are expected this year.

Prior to moving into company management, Dr Williams spent over a decade in the City as a top-rated[1] healthcare analyst, with Robertson Stephens and Lehman Brothers. As well as advising on life sciences investments, he was involved in several IPOs and M&A transactions. Sam has a biology degree from the University of Oxford and a PhD from the University of Cambridge. He will combine his duties at Conformetrix with his role as CEO of Modern Biosciences, a virtual drug development company.

Dr Clive Dix, Chairman of Conformetrix, said, "We welcome Sam as CEO of Conformetrix, where his expertise will be invaluable as the company enters this important next phase of its development. The Board's thanks are also due to Andrew and to Chief Scientific Officer and fellow founder Dr Charles Blundell for their significant contribution to the company's growth so far."

Dr Sam Williams, CEO of Conformetrix, added, "Conformetrix's technology has huge potential in the optimisation of how the pharmaceutical and biotechnology industry generates new pharmaceutical products, and I'm really pleased to be taking on this more active role within the company. The team has expanded significantly during the last year, and I look forward to working with it as Conformetrix matures and moves towards collaborative deals."

[1] Number one-ranked European Biotechnology Analyst in Institutional Investor survey 2004-2006, and in Thomson Extel survey in 2004 and 2005.

Photo available on request

About Conformetrix Ltd

Conformetrix is a Manchester, UK-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since Conformetrix's NMR technology shows what shapes molecules adopt when they are active, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has solved biostructures for several large pharmaceutical companies, as well as developing proprietary drug programmes, and has been funded since inception by specialist life science investor Aquarius Equity Partners. For more information, please go to http://www.conformetrix.com.  

For further information please contact:

Conformetrix Ltd
Sam Williams, CEO, +44(0)7881-588-947
Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185
communications@conformetrix.com


'/>"/>
SOURCE Conformetrix Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors
2. Codexis Appoints Interim Chief Executive Officer
3. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
4. UBM Live Appoints Jim Buckley as Informex Brand Director
5. Samsung Medison America Appoints Michael Podany as Vice President of Sales, West USA
6. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
7. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
8. Biosyntrx, Inc. Appoints New Board Member & New VP of Operations
9. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
10. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
11. PrimeraDx Appoints David Jackson as VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):